Active Ingredient History

  • Now
Rosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. It is FDA approved for the treatment of as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Inhibitors of CYP2C8 (e.g., gemfibrozil) may increase rosiglitazone levels; inducers of CYP2C8 (e.g., rifampin) may decrease rosiglitazone levels. Common adverse reactions include edema, weight gain, and headache.   NCATS

More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$2.8002 - $5.5627
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

avandamet | avandaryl | avandia | brl49653 | brl 49653 | brl-49653 | brl 49653c | brl-49653c | brl-49653-c | rosiflitazone | rosigilitazone | rosiglitazon | rosiglitazona | rosiglitazone | rosiglitazone / glimepiride | rosiglitazone hcl | rosiglitazone hydrochloride | rosiglitazone maleate | rosiglitazone maleate-metformin hydrochloride combination | rosiglitazone-metformin combination | rosiglitazone / metformin hydrochloride, | rosiglitazonum | rosiglizole


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue